PDE4B

From Wikipedia, the free encyclopedia
Jump to: navigation, search
PDE4B
Protein PDE4B PDB 1f0j.png
Available structures
PDB Human UniProt search: PDBe RCSB
Identifiers
Aliases PDE4B, DPDE4, PDEIVB, phosphodiesterase 4B
External IDs MGI: 99557 HomoloGene: 1953 GeneCards: PDE4B
RNA expression pattern
PBB GE PDE4B 203708 at fs.png

PBB GE PDE4B gnf1h03574 at fs.png

PBB GE PDE4B 211302 s at fs.png
More reference expression data
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001177980
NM_001177981
NM_001177982
NM_001177983
NM_019840

RefSeq (protein)

n/a

Location (UCSC) Chr 1: 65.79 – 66.37 Mb Chr 4: 102.09 – 102.61 Mb
PubMed search [1] [2]
Wikidata
View/Edit Human View/Edit Mouse

cAMP-specific 3',5'-cyclic phosphodiesterase 4B is an enzyme that in humans is encoded by the PDE4B gene.[3]

This gene is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family. Cyclic nucleotides are important second messengers that regulate and mediate a number of cellular responses to extracellular signals, such as hormones, light, and neurotransmitters. The cyclic nucleotide phosphodiesterases (PDEs) regulate the cellular concentrations of cyclic nucleotides and thereby play a role in signal transduction. This gene encodes a protein that specifically hydrolyzes cAMP. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.[3][4]

Clinical relevance[edit]

Altered activity of this protein has been associated with schizophrenia and bipolar disorder.[3] PDE4B is believed to be the PDE4 subtype involved in the antipsychotic effects of PDE4 inhibitors such as rolipram.[5] PDE4B is involved in dopamine-associated and stress-related behaviours.[6] It has also recently been found to modulate cognition, as reduction in PDE4B activity improves memory and long-term plasticity in mouse models, possibly supporting further therapeutic applications.[7]

Inhibitors[edit]

AN2728, a boron-containing drug candidate that as of 2015 was under development by Anacor Pharmaceuticals for the topical treatment of psoriasis and atopic dermatitis (atopic eczema).[8][9][10] mainly acting on PDE4B.[10]

References[edit]

  1. ^ "Human PubMed Reference:". 
  2. ^ "Mouse PubMed Reference:". 
  3. ^ a b c "Entrez Gene: PDE4B phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila)". 
  4. ^ Swerdlow, Neal R. (2010-08-19). Behavioral Neurobiology of Schizophrenia and Its Treatment. Springer Science & Business Media. ISBN 9783642137174. 
  5. ^ Porteous DJ, Millar JK, Brandon NJ, Sawa A (Dec 2011). "DISC1 at 10: connecting psychiatric genetics and neuroscience". Trends in Molecular Medicine. 17 (12): 699–706. PMC 3253483Freely accessible. PMID 22015021. doi:10.1016/j.molmed.2011.09.002. 
  6. ^ Francis, SH; Conti, M; Houslay, MD, eds. (2011). Phosphodiesterases as Drug Targets (PDF). Handbook of Experimental Pharmacology. 204. Springer Berlin Heidelberg. ISBN 978-3-642-17968-6. doi:10.1007/978-3-642-17969-3. 
  7. ^ http://newsdaily.com/2015/08/scientists-researching-brain-disorders-create-super-clever-mice/
  8. ^ Anacor AN2728 at Anacor website Page accessed May 15, 2015
  9. ^ Nazarian R, Weinberg JM (Nov 2009). "AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis". Current Opinion in Investigational Drugs. 10 (11): 1236–42. PMID 19876791. 
  10. ^ a b Moustafa F, Feldman SR (May 2014). "A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology". Dermatol Online J. 20 (5): 22608. PMID 24852768. 

Further reading[edit]